Skip to main content
Clinical Trials/KCT0008510
KCT0008510
Completed
未知

Development of early dementia imaging marker by using a quantitative susceptibility mapping (QSM) and blood brain barrier (BBB) permeability imaging

Konkuk University Medical Center0 sites75 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Konkuk University Medical Center
Enrollment
75
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
January 6, 2021
Last Updated
2 years ago
Study Type
Observational Study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Age 45 to 80 years old.
  • \- Individuals who have agreed to participate in the clinical trial and voluntarily signed the written informed consent form.
  • \- Patients who clinically correspond to the normal aging group or patients who meet the clinical diagnostic criteria for Mild Cognitive Impairment according to the 2011 NIA\-AA (National Institute on Aging\-Alzheimer's Association) guidelines.
  • \- Primarily, patients who have undergone an amyloid PET scan, if possible, are the primary targets.

Exclusion Criteria

  • Exclusion criteria include individuals with a history of drug addiction, past or current neurological, psychiatric, neurosurgical diseases, or head trauma. Those who have taken psychiatric medications at doses higher than the therapeutic range that could affect brain waves in the past three months are also excluded. The study targets only individuals found to be free from dementia, based on a medical history survey, neurological examination, and cognitive function test conducted by a neurology specialist.

Outcomes

Primary Outcomes

Not specified

Similar Trials